Currently, there are 74.34M common shares owned by the public and among those 65.47M shares have been available to trade.
The company’s stock has a 5-day price change of 50.75% and 63.64% over the past three months. SWTX shares are trading 49.46% year to date (YTD), with the 12-month market performance up to 20.67% higher. It has a 12-month low price of $28.21 and touched a high of $53.92 over the same period. SWTX has an average intraday trading volume of 1.48 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 44.27%, 40.38%, and 43.65% respectively.
Institutional ownership of SpringWorks Therapeutics Inc (NASDAQ: SWTX) shares accounts for 101.96% of the company’s 74.34M shares outstanding.
It has a market capitalization of $4.02B and a beta (3y monthly) value of 0.85. The earnings-per-share (ttm) stands at -$3.73. Price movements for the stock have been influenced by the stock’s volatility, which stands at 15.61% over the week and 9.78% over the month.
Earnings per share for the fiscal year are expected to increase by 40.97%, and 34.76% over the next financial year. EPS should grow at an annualized rate of 54.27% over the next five years, compared to -65.72% over the past 5-year period.
Looking at the support for the SWTX, a number of firms have released research notes about the stock. Evercore ISI stated their Outperform rating for the stock in a research note on November 20, 2024, with the firm’s price target at $60. Guggenheim coverage for the SpringWorks Therapeutics Inc (SWTX) stock in a research note released on February 05, 2024 offered a Buy rating with a price target of $75. BofA Securities was of a view on December 01, 2022 that the stock is Buy, while H.C. Wainwright gave the stock Buy rating on January 19, 2021, issuing a price target of $87- $101. H.C. Wainwright on their part issued Buy rating on October 29, 2020.
